Advertisement

Topics

Quizartinib Poised to Expand FLT3 Inhibition Options in AML

09:58 EDT 16 Apr 2019 | OncLive

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Original Article: Quizartinib Poised to Expand FLT3 Inhibition Options in AML

NEXT ARTICLE

More From BioPortfolio on "Quizartinib Poised to Expand FLT3 Inhibition Options in AML"

Advertisement
Quick Search
Advertisement
Advertisement